// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























169 Abstracts

Serum Cystatin C on Admission: A Potential Predictor for Hospital-Acquired AKI in Patients with an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

DaweiChen - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

The Difference Between eGFR by Cystatin C vs. Creatinine Provides Clinical Information About Frailty in CHS

O. AlisonPotok - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The Difference Between eGFR by Cystatin C vs. Creatinine Provides Clinical Information About Frailty in SPRINT

O. AlisonPotok - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Albuminuria

N/A

Serum Creatinine, Cystatin C, and a Comparison of Estimated Glomerular Filtration Rates in Very Low Birth Weight Children at 6 Years Old

MasafumiOka - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

Serum Cystatin C Levels at Birth in Very-Low-Birth-Weight Infants

MarikoSawada - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Congenital anomalies

N/A

Evaluation of Renal and Retinal Outcomes in the Northern Ireland Cohort of Longitudinal Ageing (NICOLA)

RachaelO'Neill - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Fluvastatin

Efficacy of Low-Intensity Pulsed Ultrasound on Renal Fibrosis and Progression of CKD in a Mouse Model

Chih-KangChiang - American Society of Nephrology (ASN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Kidney fibrosis

Superoxide dismutase

IS THERE ANY IMPORTANCE TO DETERMINE OF UROMODULIN SERUM CONCENTRATION IN PATIENTS WITH LONG TERM DIABETES MELLITUS TYPE 2

Elena Jordanova - European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

ASSOCIATION BETWEEN EARLY IMPARMENT IN RENAL FUNCTION AND CHANGES IN CARDIAC STRUCTURE AND FUNCTION

Liana Xhakollari - European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Angiotensin II

APLICATION OF SERUM CYSTATIN C FOR PREDICTION OF NEPHROPATHY AND CARDIOVASCULAR DISEASES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Nevi Pasko - European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

A SINGLE-ARM TRIAL EVALUATING THE SAFETY AND EFFICACY OF METFORMIN IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Bogdan Sorohan - European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

Metformin Hydrochloride

CYSTATIN C IN CKD1-3 STAGES IN CHILDREN

Dmytro Ivanov - European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

RENAL FUNCTION AMONG MIDDLE EASTERN IMMIGRANTS IN SWEDEN AND ITS ASSOCIATION TO PRO-ENKEPHALIN

Christopher Nilsson - European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Adipose Tissue-Derived Stem Cells (ASC) Reverses Kidney Disease Progression in SHR Rats Induced to Metabolic Syndrome

MarceloCostaBatista - American Society of Nephrology (ASN) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Comparison of eGFR with Creatinine and Cystatin C by eCKD-EPI in CKD Patients with and without Hypoalbuminemia

Carlos Federico�Varela - American Society of Nephrology (ASN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Creatinine versus Cystatin C: Is There Any Benefit in Using a Cystatin C Based Equation for Assessment of CKD in Older Adults?

ShahrzadZonoozi - American Society of Nephrology (ASN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prediction of Mortality in Elderly Patients with CKD – The Role of Cystatin C and Other GFR Markers

SebastjanBevc - American Society of Nephrology (ASN) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Serum Cystatin C for the Assessment of Renal Function Prior to Chemotherapy

R. Allchin - British Society for Hematology (BSH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Methotrexate

Clinical Determinants and Relation to Prognosis of Progressive Tubular Damage and Glomerular Decline in Chronic Heart Failure (Bio-SHiFT Study)

Milos Brankovic - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Cystatin C and Left Ventricle Function in Black Patients With Atrial Fibrillation and Acute Coronary Syndrome

Haroon Kamran - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved